Reciprocal Modulation of Serum Amylin and Alanine Aminopeptidase in Infertile Men Treated with Motility Max or Q-well10: A Before-and-After Study with Parallel Changes in Sperm Output

Abstract

Background. Male factor underlies roughly half of infertility, yet accessible serum markers of treatment response are scarce. Amylin (islet amyloid polypeptide, IAPP) and alanine aminopeptidase (AAP; aminopeptidase N, APN) link metabolism and the reproductive tract, but their behaviour during pro-fertility therapy is unknown. Aim. To measure serum amylin and AAP in infertile men before and after Motility Max or Q-well10, and to relate their changes to sperm output. Methods. In this before-and-after study, 60 infertile men (20–49 years), stratified into three age groups, gave paired sera. Amylin was assayed by enzyme-linked immunosorbent assay (ELISA) and AAP by automated kinetic chemistry; total sperm count followed WHO 2021 methods. Means were compared by analysis of variance (ANOVA); within rows, unlike letters denote P < 0.05. Results. Amylin rose after treatment in younger men (Motility Max, 20–29 years: 11.27 ± 1.10 to 20.87 ± 1.90 ng/mL; P < 0.05), with a weaker response at 40–49 years. AAP fell in most groups (Motility Max, 20–29 years: 23.59 ± 2.02 to 13.21 ng/mL; P < 0.05) and converged near 13–14 ng/mL. Total sperm count roughly doubled in the youngest stratum. Conclusion. A rise in amylin and a fall in AAP tracked improved sperm output, positioning both as candidate serum markers of response. Correlation-based, controlled trials are needed.